Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 8, 2024 and accepted by EDGAR at Aug 8, 2024, 16:04 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $145.3m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $290.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-04-01 to 2024-06-30 | $54.5m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2024-01-01 to 2024-06-30 | $107.9m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-04-01 to 2024-06-30 | $90.8m | us-gaap:GrossProfit |
| Gross profit | 6 months2024-01-01 to 2024-06-30 | $182.3m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-04-01 to 2024-06-30 | $43.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2024-01-01 to 2024-06-30 | $85.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | $47.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | $96.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $15.6m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $32.9m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2024-04-01 to 2024-06-30 | $9.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2024-01-01 to 2024-06-30 | $18.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-04-01 to 2024-06-30 | $19.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | $47.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | $0.52 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | $1.24 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | $0.60 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | $1.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 40,383,694 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 40,510,943 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | $129.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2024-01-01 to 2024-06-30 | $838.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2024-01-01 to 2024-06-30 | $35.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2024-06-30 | $172.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $510.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $1.05bn | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $461.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $836.8m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-06-30 | $216.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-24-011586. Last ingested by Listed: Nov 5, 2026, 12:06 ET. Listed shows no prices and gives no investment advice.